Prognia
Drug Database
🇪🇺EU · EMAApplication withdrawnATC: L01FX35

Datopotamab deruxtecan Daiichi Sankyo(datopotamab deruxtecan)

Carcinoma, Non-Small-Cell Lung

Marketing Authorisation Holder: Daiichi Sankyo Europe GmbH

INN: datopotamab deruxtecan

Indication

Treatment of adult patients with locally advanced or metastatic non squamous non-small cell lung cancer (NSCLC)

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Datopotamab deruxtecan Daiichi Sankyo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.